New Search
If you are not happy with the results below please do another searchMonday October 16, 1:30pm-2:45pm CT How can funders move more of their funded research towards clinical relevance? This session explored specific things philanthropic funders can do to increase the likelihood of improving patient outcomes. It included a contextual update on how the research, regulatory, and commercial landscapes are changing, and how this might shift the highest impact funding opportunities for foundations. It focused on how funders can help drive research findings into clinical practice, including strategies to empower stakeholders throughout the pipeline to work across cultural and professional boundaries. Relevant resources shared by Chris Austin after the session: National Center... read more →
Under development by the Drug and Other Therapy Development working group, this “toolkit of toolkits” will enable member organizations to more easily identify and access existing and up-to-date resources relevant to DOTD working group goals. Drug and Other Therapy Development References U.S. Food and Drug Administration - for the latest developments in regulatory policies and regulatory science. National Institute of Neurological Disorders and Stroke - resources and tools needed to advance the fundamental knowledge about the brain and nervous system and to use that knowledge to reduce the burden of neurological disease. QB3 - hub for innovation and entrepreneurship in the life sciences: a... read more →